Logo

Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept

Share this

Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept

Shots:

  • GTS and Kishi Kasei will jointly develop biosimilar of Aflibercept and will form a manufacturing process for the drug substance utilizing high-yield protein-producing cell lines- which were jointly developed by GTS and Fuso Pharmaceutical
  • The collaboration focusses to secure a future revenue base via commercialization of biosimilar of Aflibercept and to gain market share in ophthalmologic diseases
  • The companies will partner with others to jointly promote drug development- non-clinical studies- clinical studies- manufacturing and approvals- sales- etc. and create a business structure for commercialization of the product

Click here to­ read full press release/ article | Ref: GTS | Image: Kabu Fx Trends


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions